TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04229342

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per-oral endoscopic myotomy
Description: Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic myotomy
Description: Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy.
Study: NCT03720639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM
Description: Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM
Description: Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
Study: NCT04468555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural reeducation
Description: It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
Study: NCT02023476

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI- imaging on the upper arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI- imaging on the upper arm
Study: NCT03907150

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain ultrasound
Description: Post-interpretation of recorded ultrasound loops

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain ultrasound
Description: Post-interpretation of recorded ultrasound loops
Study: NCT00661817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program
Description: Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care and Reading Materials
Description: Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2.
Study: NCT01024842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv low dose
Description: Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo low dose
Description: Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv high dose
Description: Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo high dose
Description: Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
Study: NCT02718716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: * Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: * Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: * Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: * Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7665
Description: * Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion
Study: NCT02856204

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood
Study: NCT01087047

Intervention type: DEVICE
Intervention: Acoustic reflection method
Description: An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.

Intervention type: DEVICE
Intervention: Acoustic reflection method
Description: An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
Study: NCT01341886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
Study: NCT02519712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-PBSC Infusion
Description: G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
Study: NCT01249612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermotherapy
Description: Knee joint icing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thermotherapy
Description: Elbow joint icing
Study: NCT02246803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+Pulmonary vein isolation procedure
Description: Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated CABG
Description: Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
Study: NCT00649675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Tablets 15 mg
Description: 15mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® Tablets 15 mg
Description: 15mg, single dose fed
Study: NCT01124643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replagal
Description: 0.2 mg/kg administered intravenously \[IV\] every other week
Study: NCT00291668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use
Study: NCT03919877

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary
Description: Dietary counseling based on results of CGM analyses.
Study: NCT02958449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test - Standard Closure with TissuGlu Surgical Adhesive
Description: Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
Study: NCT01666301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals
Study: NCT01190839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
Study: NCT00850213

Intervention type: DEVICE
Intervention: Endeavor Resolute Stent
Description: Single implantation
Study: NCT01667731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03398902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual sleep
Description: The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
Study: NCT01667731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04531891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Description: During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Description: During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
Study: NCT03405480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation
Study: NCT01662804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3F8 Monoclonal Antibody Combined with Interleukin-2
Description: One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
Study: NCT03507452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).
Study: NCT02809651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
Study: NCT02733536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard endotracheal tube
Description: 1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard endotracheal tube
Description: 1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
Study: NCT02809651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
Study: NCT00757380

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trypan Blue
Description: Membranepeeling with TB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brillant Blue
Description: Membranepeeling and membrana limitans interna peeling with BB
Study: NCT00781027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Comparison of longitudinal phacoemulsification and torsional phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Comparison of longitudinal phacoemulsification and torsional phacoemulsification
Study: NCT03997695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise group
Description: The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
Study: NCT02856204

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03616509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: 12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
Study: NCT03997695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercise plus kinesio taping group
Description: The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
Study: NCT03388450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Enteral 1000 mg omega 3 fatty acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enteral nutrition without omega 3 fatty acid.
Study: NCT03616509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 months on placebo, sodium chloride 0,9% injections
Study: NCT03507452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).
Study: NCT03236701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg White replacement
Description: Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
Study: NCT01106066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, S-1, radiotherapy
Description: Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
Study: NCT04619043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Orthotic
Study: NCT00508872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
Study: NCT01438281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: SYL1001 eye drops. topical administration
Study: NCT03507452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2287411
Description: Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation.
Study: NCT03462628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI plus low-voltage substrate modification
Description: CPVI plus low-voltage substrate modification in the left atrium during SR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI alone
Description: circumferential pulmonary vein isolation
Study: NCT03122327

Intervention type: OTHER
Intervention: Questionaires
Description: Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
Study: NCT03316573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
Study: NCT01084096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increasing use of Antenatal Corticosteroids (ACS)
Description: Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants.